Forte Biosciences logo
FBRXForte Biosciences
Trade FBRX now
Forte Biosciences primary media

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) focuses on advancing the science and treatment of patients battling inflammatory skin diseases. Using a combination of biotechnology and a deep understanding of dermatological conditions, Forte is committed to developing innovative therapies. The company's projects primarily revolve around leveraging their proprietary technology platforms to create treatments that are both effective and safe for patients suffering from conditions such as psoriasis, atopic dermatitis, and other inflammatory skin diseases. At the core of Forte's objectives, is the ambition to significantly improve the quality of life for patients by offering novel solutions that address unmet clinical needs in the dermatology space. Their efforts are directed towards not only discovering and developing new drugs but also ensuring these advancements are accessible to the individuals who need them most.

What is FBRX known for?

Snapshot

Public US
Ownership
2007
Year founded
9
Employees
Dallas, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Dallas, US

Products and/or services of Forte Biosciences

  • Development of a novel topical therapy aimed at treating inflammatory skin diseases by targeting the immune system.
  • Research into precision biologics for addressing severe immune disorders.
  • Collaboration with academic institutions to discover new immunomodulatory compounds.
  • Partnership with technology firms to enhance drug delivery methods for skin conditions.
  • Initiative to leverage artificial intelligence for predicting drug efficacy in dermatological treatments.
  • Contribution to clinical trials focused on advancing therapies for autoimmune skin diseases.

Forte Biosciences executive team

  • Dr. Paul A. Wagner Ph.D.CEO, President & Chairman
  • Mr. Antony A. Riley CPAChief Financial Officer
  • Dr. Barbara K. Finck M.D.Chief Medical Clinician & Director
  • Mr. Christopher RoenfeldtChief Operating Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.